Table 4.

TPOAb and thyroid dysfunction during Alemtuzumab treatment.

Patients and TPOAb	(%)
Patients with postive TPOAb at baseline	8.0
Patients with negative TPOAb at baseline who develop thyroid dysfunction	31.0
Patients with postive TPOAb at baseline who develop thyroid dysfunction	69.0
Graves’ hyperthyroidism Hypothyroidism Destructive thyroiditis Euthyroidism	31.2 25.0 12.5 31.2
Positive TPOAb at the time of thyroid dysfunction	69.8
Positive TPOAb at baseline De novo positive TPOAb Persistently positive TPOAb	15.1 54.8 30.1
De novo positive TPOAb without thyroid dysfunction	10.5

Data elaborated from Daniels et al. (42).